Bethesda, Maryland, United States Cystic Fibrosis Foundation appeared to be the Corporate Investor, which was created in 1955. The main department of described Corporate Investor is located in the Bethesda. The company was established in North America in United States.
Considering the real fund results, this Corporate Investor is 26 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2006. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Cystic Fibrosis Foundation works on 2 percentage points more the average amount of lead investments.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Cystic Fibrosis Foundation, startups are often financed by Epidarex Capital, Imperial Innovations, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Aligo Innovation, Shionogi, RSJ Investments SICAV a.s.. In the next rounds fund is usually obtained by U.S. Venture Partners (USVP), RBC Capital Markets, Novo Holdings.
The fund has exact preference in some founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biopharma. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline 4D Molecular Therapeutics, Laurent Pharmaceuticals, Parion Sciences
Related Funds
| Fund Name | Location |
| Arcus Ventures | New York, New York, United States |
| Dia Vikas Capital | Gurgaon, Haryana, India |
| Ebara Corporation | Japan, Tokyo |
| Elephant | Boston, Massachusetts, United States |
| Entresmart | - |
| First Capital Partners | Nebraska, Omaha, United States |
| French Investment Fund | - |
| Hangzhou Chuangyu Touzi Zixun Co., Ltd. | China, Hangzhou, Zhejiang |
| Hankyu | Japan, Osaka, Osaka Prefecture |
| Mustard Seed | England, London, United Kingdom |
| New Jersey Devils | New Jersey, Newark, United States |
| Ningxia Ruixue Guquan Touzi | China, Ningxia, Yinchuan |
| Tech Transfer UPV | Spain, Valencia, Valencian Community |
| TrustBIX | Alberta, Canada, Edmonton |
| W.R. Huff Asset Management Co. LLC. | Florida, Stuart, United States |
| Yorkshire Bank | England, Leeds, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Sionna Therapeutics | $182M | 06 Mar 2024 | Natick, Massachusetts, United States | ||
SomaServe | $27M | 13 Nov 2023 | Cambridge, England, United Kingdom | ||
Nanite | $2M | 15 Mar 2023 | Boston, Massachusetts, United States | ||
Pulmocide | $52M | 06 Dec 2022 | London, England, United Kingdom | ||
Carmine Therapeutics | 13 Oct 2022 | Cambridge, Massachusetts, United States | |||
Carbon Biosciences | $38M | 21 Jun 2022 | Lexington, Massachusetts, United States | ||
Sionna Therapeutics | $110M | 19 Apr 2022 | Natick, Massachusetts, United States | ||
SalioGen Therapeutics | $115M | 05 Jan 2022 | Burlington, Massachusetts, United States | ||
| $28M | 13 May 2021 | Jerusalem, Jerusalem District, Israel |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Sionna Therapeutics | $182M | 06 Mar 2024 | Natick, Massachusetts, United States | ||
SomaServe | $27M | 13 Nov 2023 | Cambridge, England, United Kingdom | ||
Nanite | $2M | 15 Mar 2023 | Boston, Massachusetts, United States | ||
Pulmocide | $52M | 06 Dec 2022 | London, England, United Kingdom | ||
Carmine Therapeutics | 13 Oct 2022 | Cambridge, Massachusetts, United States | |||
Carbon Biosciences | $38M | 21 Jun 2022 | Lexington, Massachusetts, United States | ||
Sionna Therapeutics | $110M | 19 Apr 2022 | Natick, Massachusetts, United States | ||
SalioGen Therapeutics | $115M | 05 Jan 2022 | Burlington, Massachusetts, United States | ||
| $28M | 13 May 2021 | Jerusalem, Jerusalem District, Israel |
